Amylyx Pharmaceuticals In...

NASDAQ: AMLX · Real-Time Price · USD
5.08
-0.07 (-1.36%)
At close: Jun 02, 2025, 3:59 PM
5.21
2.67%
After-hours: Jun 02, 2025, 04:05 PM EDT

Amylyx Pharmaceuticals Statistics

Share Statistics

Amylyx Pharmaceuticals has 89.14M shares outstanding. The number of shares has increased by 30.29% in one year.

Shares Outstanding 89.14M
Shares Change (YoY) 30.29%
Shares Change (QoQ) 29.26%
Owned by Institutions (%) 73.12%
Shares Floating n/a
Failed to Deliver (FTD) Shares 1,672
FTD / Avg. Volume 0.18%

Short Selling Information

The latest short interest is 4.97M, so 5.58% of the outstanding shares have been sold short.

Short Interest 4.97M
Short % of Shares Out 5.58%
Short % of Float 6.16%
Short Ratio (days to cover) 4.43

Valuation Ratios

The PE ratio is -0.85 and the forward PE ratio is -3.68. Amylyx Pharmaceuticals's PEG ratio is 0.

PE Ratio -0.85
Forward PE -3.68
PS Ratio 2.95
Forward PS 2.8
PB Ratio 1.56
P/FCF Ratio -1.53
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Amylyx Pharmaceuticals.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.67, with a Debt / Equity ratio of 0.01.

Current Ratio 6.67
Quick Ratio 6.67
Debt / Equity 0.01
Debt / EBITDA -0.01
Debt / FCF -0.01
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $710,333.33
Profits Per Employee $-2,453,195.12
Employee Count 123
Asset Turnover 0.45
Inventory Turnover n/a

Taxes

Income Tax -393K
Effective Tax Rate 0.13%

Stock Price Statistics

The stock price has increased by 198.26% in the last 52 weeks. The beta is -0.59, so Amylyx Pharmaceuticals's price volatility has been lower than the market average.

Beta -0.59
52-Week Price Change 198.26%
50-Day Moving Average 4.41
200-Day Moving Average 3.95
Relative Strength Index (RSI) 56.51
Average Volume (20 Days) 926,667

Income Statement

In the last 12 months, Amylyx Pharmaceuticals had revenue of 87.37M and earned -301.74M in profits. Earnings per share was -4.43.

Revenue 87.37M
Gross Profit -37.26M
Operating Income -314.73M
Net Income -301.74M
EBITDA -301.23M
EBIT -291.88M
Earnings Per Share (EPS) -4.43
Full Income Statement

Balance Sheet

The company has 77.39M in cash and 1.98M in debt, giving a net cash position of 75.41M.

Cash & Cash Equivalents 77.39M
Total Debt 1.98M
Net Cash 75.41M
Retained Earnings -606.69M
Total Assets 219.68M
Working Capital 198.21M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -167.65M and capital expenditures -157K, giving a free cash flow of -167.8M.

Operating Cash Flow -167.65M
Capital Expenditures -157K
Free Cash Flow -167.8M
FCF Per Share -2.46
Full Cash Flow Statement

Margins

Gross margin is -42.65%, with operating and profit margins of -360.22% and -345.36%.

Gross Margin -42.65%
Operating Margin -360.22%
Pretax Margin -345.81%
Profit Margin -345.36%
EBITDA Margin -344.77%
EBIT Margin -360.22%
FCF Margin -192.06%

Dividends & Yields

AMLX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for AMLX is $10.5, which is 104.7% higher than the current price. The consensus rating is "Buy".

Price Target $10.5
Price Target Difference 104.7%
Analyst Consensus Buy
Analyst Count 6
Stock Forecasts

Scores

Altman Z-Score 8.44
Piotroski F-Score 3